{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:20:46Z","timestamp":1790266846987,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12664-020-01114-y","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:03:34Z","timestamp":1614960214000},"page":"5-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-4854","authenticated-orcid":false,"given":"Janine S. Y.","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet K.","family":"Coller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive A.","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"1114_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1114_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253\u201362.","journal-title":"Radiother Oncol"},{"key":"1114_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499\u2013511.","journal-title":"Nat Rev Immunol"},{"key":"1114_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.","journal-title":"Front Immunol"},{"key":"1114_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","volume":"13","author":"T Kawai","year":"2006","unstructured":"Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13:816\u201325.","journal-title":"Cell Death Differ"},{"key":"1114_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nri.2016.116","volume":"17","author":"T Worbs","year":"2017","unstructured":"Worbs T, Hammerschmidt SI, F\u00f6rster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17:30\u201348.","journal-title":"Nat Rev Immunol"},{"key":"1114_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1057","volume":"3","author":"AM Mowat","year":"2003","unstructured":"Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3:331\u201341.","journal-title":"Nat Rev Immunol"},{"key":"1114_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1440-1746.2011.06839.x","volume":"27","author":"L Dong","year":"2012","unstructured":"Dong L, Li J, Liu Y, et al. Toll-like receptor 2 monoclonal antibody or\/and toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol. 2012;27:110\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1114_CR9","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1371\/journal.pone.0000662","volume":"2","author":"MM Heimesaat","year":"2007","unstructured":"Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via toll-like receptors 2 and 4. PLoS One. 2007;2:e662.","journal-title":"PLoS One"},{"key":"1114_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1189\/jlb.0607358","volume":"83","author":"SC Gribar","year":"2008","unstructured":"Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol. 2008;83:493\u20138.","journal-title":"J Leukoc Biol"},{"key":"1114_CR11","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.4049\/jimmunol.0901271","volume":"183","author":"K Takahashi","year":"2009","unstructured":"Takahashi K, Sugi Y, Hosono A, Kaminogawa S. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J Immunol. 2009;183:6522\u20139.","journal-title":"J Immunol"},{"key":"1114_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/41131","volume":"388","author":"R Medzhitov","year":"1997","unstructured":"Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature. 1997;388:394\u20137.","journal-title":"Nature."},{"key":"1114_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/ar1469","volume":"7","author":"T Kawai","year":"2005","unstructured":"Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005;7:12\u20139.","journal-title":"Arthritis Res Ther"},{"key":"1114_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.biochem.76.060305.151318","volume":"76","author":"NJ Gay","year":"2007","unstructured":"Gay NJ, Gangloff M. Structure and function of toll receptors and their ligands. Annu Rev Biochem. 2007;76:141\u201365.","journal-title":"Annu Rev Biochem"},{"key":"1114_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fimmu.2014.00473","volume":"5","author":"A Liaunardy-Jopeace","year":"2014","unstructured":"Liaunardy-Jopeace A, Gay NJ. Molecular and cellular regulation of toll-like receptor-4 activity induced by lipopolysaccharide ligands. Front Immunol. 2014;5:473.","journal-title":"Front Immunol"},{"key":"1114_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1172\/JCI6709","volume":"104","author":"S Frantz","year":"1999","unstructured":"Frantz S, Kobzik L, Kim Y-D, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271\u201380.","journal-title":"J Clin Invest"},{"key":"1114_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jnr.20767","volume":"83","author":"T Kielian","year":"2006","unstructured":"Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res. 2006;83:711\u201330.","journal-title":"J Neurosci Res"},{"key":"1114_CR18","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1074\/jbc.M310859200","volume":"279","author":"KR Taylor","year":"2004","unstructured":"Taylor KR, Trowbridge JM, Rudisill JA, et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem. 2004;279:17079\u201384.","journal-title":"J Biol Chem"},{"key":"1114_CR19","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.4049\/jimmunol.177.5.3273","volume":"177","author":"T Jilling","year":"2006","unstructured":"Jilling T, Simon D, Lu J, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol. 2006;177:3273\u201382.","journal-title":"J Immunol"},{"key":"1114_CR20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/nature07830","volume":"458","author":"BS Park","year":"2009","unstructured":"Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4\u2013MD-2 complex. Nature. 2009;458:1191\u20136.","journal-title":"Nature."},{"key":"1114_CR21","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.4049\/jimmunol.167.3.1609","volume":"167","author":"MT Abreu","year":"2001","unstructured":"Abreu MT, Vora P, Faure E, et al. Decreased expression of toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001;167:1609\u201316.","journal-title":"J Immunol"},{"key":"1114_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1165\/ajrcmb.17.1.f132","volume":"17","author":"TS Blackwell","year":"1997","unstructured":"Blackwell TS, Christman JW. The role of nuclear factor- \u03ba B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997;17:3\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1114_CR23","doi-asserted-by":"publisher","first-page":"e111460","DOI":"10.1371\/journal.pone.0111460","volume":"9","author":"GL Hold","year":"2014","unstructured":"Hold GL, Berry S, Saunders KA, et al. The TLR4 D299G and T399I SNPs are constitutively active to up-regulate expression of TRIF-dependent genes. PLoS One. 2014;9:e111460.","journal-title":"PLoS One"},{"key":"1114_CR24","doi-asserted-by":"publisher","first-page":"16645","DOI":"10.1073\/pnas.0704828104","volume":"104","author":"B Ferwerda","year":"2007","unstructured":"Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A. 2007;104:16645\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1114_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/WNR.0000000000000140","volume":"25","author":"JR Weinstein","year":"2014","unstructured":"Weinstein JR, Schulze J, Lee RV, et al. Functional polymorphisms in toll-like receptor 4 are associated with worse outcome in acute ischemic stroke patients. Neuroreport. 2014;25:580\u20134.","journal-title":"Neuroreport."},{"key":"1114_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/mi.2013.13","volume":"6","author":"M Fukata","year":"2013","unstructured":"Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol. 2013;6:451\u201363.","journal-title":"Mucosal Immunol"},{"key":"1114_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/cei.12381","volume":"178","author":"M Brown","year":"2014","unstructured":"Brown M, Hughes KR, Moossavi S, et al. Toll-like receptor expression in crypt epithelial cells, putative stem cells and intestinal myofibroblasts isolated from controls and patients with inflammatory bowel disease. Clin Exp Immunol. 2014;178:28\u201339.","journal-title":"Clin Exp Immunol"},{"key":"1114_CR28","doi-asserted-by":"publisher","first-page":"e42777","DOI":"10.1371\/journal.pone.0042777","volume":"7","author":"L Belmonte","year":"2012","unstructured":"Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One. 2012;7:e42777.","journal-title":"PLoS One"},{"key":"1114_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1136\/gut.2003.030205","volume":"53","author":"D Franchimont","year":"2004","unstructured":"Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn\u2019s disease and ulcerative colitis. Gut. 2004;53:987\u201392.","journal-title":"Gut."},{"key":"1114_CR30","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1053\/j.gastro.2007.09.008","volume":"133","author":"M Fukata","year":"2007","unstructured":"Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869\u201381.","journal-title":"Gastroenterology."},{"key":"1114_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1152\/ajpgi.00328.2004","volume":"288","author":"M Fukata","year":"2005","unstructured":"Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:1055\u201365.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1114_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1152\/ajpgi.00465.2012","volume":"306","author":"J Zhang","year":"2014","unstructured":"Zhang J, Dou W, Zhang E, et al. Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2014;306:27\u201336.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1114_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1440-1746.2009.06046.x","volume":"25","author":"Y Liu","year":"2010","unstructured":"Liu Y, Zhang Z, Wang L, et al. TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice. J Gastroenterol Hepatol. 2010;25:209\u201314.","journal-title":"J Gastroenterol Hepatol"},{"key":"1114_CR34","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.4049\/jimmunol.174.10.6416","volume":"174","author":"MM Fort","year":"2005","unstructured":"Fort MM, Mozaffarian A, St\u00f6ver AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005;174:6416\u201323.","journal-title":"J Immunol"},{"key":"1114_CR35","doi-asserted-by":"publisher","first-page":"G1167","DOI":"10.1152\/ajpgi.90496.2008","volume":"296","author":"R Ungaro","year":"2009","unstructured":"Ungaro R, Fukata M, Hsu D, et al. A novel toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1167\u2013G79.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1114_CR36","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/ibd\/izz011","volume":"25","author":"HR Wardill","year":"2019","unstructured":"Wardill HR, Choo JM, Dmochowska N, et al. Acute colitis drives tolerance by persistently altering the epithelial barrier and innate and adaptive immunity. Inflamm Bowel Dis. 2019;25:1196\u2013207.","journal-title":"Inflamm Bowel Dis"},{"key":"1114_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nri2340","volume":"8","author":"JH Cho","year":"2008","unstructured":"Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458\u201366.","journal-title":"Nat Rev Immunol"},{"key":"1114_CR38","doi-asserted-by":"publisher","first-page":"493012","DOI":"10.1155\/2015\/493012","volume":"2015","author":"BRR de Mattos","year":"2015","unstructured":"de Mattos BRR, Garcia MPG, Nogueira JB, et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediat Inflamm. 2015;2015:493012.","journal-title":"Mediat Inflamm"},{"key":"1114_CR39","doi-asserted-by":"publisher","first-page":"G7","DOI":"10.1152\/ajpgi.00079.2004","volume":"287","author":"SH Itzkowitz","year":"2004","unstructured":"Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7\u2013G17.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1114_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u201354.","journal-title":"Gastroenterology"},{"key":"1114_CR41","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/j.1440-1746.2007.04930.x","volume":"22","author":"PR Gibson","year":"2007","unstructured":"Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn\u2019s disease. J Gastroenterol Hepatol. 2007;22:1306\u201312.","journal-title":"J Gastroenterol Hepatol"},{"key":"1114_CR42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.crohns.2013.11.017","volume":"8","author":"PR Gibson","year":"2014","unstructured":"Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2014;8:598\u2013606.","journal-title":"J Crohns Colitis"},{"key":"1114_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/ncpgasthep0528","volume":"3","author":"RB Sartor","year":"2006","unstructured":"Sartor RB. Mechanisms of disease: pathogenesis of Crohn\u2019s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390\u2013407.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"1114_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1756283X09102329","volume":"2","author":"S Garud","year":"2009","unstructured":"Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Ther Adv Gastroenterol. 2009;2:99\u2013108.","journal-title":"Ther Adv Gastroenterol"},{"key":"1114_CR45","first-page":"661","volume":"98","author":"B Veauthier","year":"2018","unstructured":"Veauthier B, Hornecker JR. Crohn\u2019s disease: diagnosis and management. Am Fam Physician. 2018;98:661\u20139.","journal-title":"Am Fam Physician"},{"key":"1114_CR46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-006-0055-4","volume":"14","author":"JA Jones","year":"2006","unstructured":"Jones JA, Avritscher EB, Cooksley CD, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505\u201315.","journal-title":"Support Care Cancer"},{"key":"1114_CR47","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.28592","volume":"120","author":"RV Lalla","year":"2014","unstructured":"Lalla RV, Bowen J, Barasch A, et al. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453\u201361.","journal-title":"Cancer."},{"key":"1114_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1046\/j.1365-2036.2003.01784.x","volume":"18","author":"M Duncan","year":"2003","unstructured":"Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther. 2003;18:853\u201374.","journal-title":"Aliment Pharmacol Ther"},{"key":"1114_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/SPC.0000000000000202","volume":"10","author":"E Cario","year":"2016","unstructured":"Cario E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Curr Opin Support Palliat Care. 2016;10:157\u201364.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1114_CR50","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1007\/s00520-019-04892-0","volume":"27","author":"JM Bowen","year":"2019","unstructured":"Bowen JM, Gibson RJ, Coller JK, et al. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer. 2019;27:4011\u201322.","journal-title":"Support Care Cancer"},{"key":"1114_CR51","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.11671","volume":"98","author":"LS Elting","year":"2003","unstructured":"Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531\u20139.","journal-title":"Cancer."},{"key":"1114_CR52","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.20162","volume":"100","author":"ST Sonis","year":"2004","unstructured":"Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995\u20132025.","journal-title":"Cancer."},{"key":"1114_CR53","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0990","volume":"15","author":"HR Wardill","year":"2016","unstructured":"Wardill HR, Gibson RJ, Van Sebille YZA, et al. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther. 2016;15:1376\u201386.","journal-title":"Mol Cancer Ther"},{"key":"1114_CR54","doi-asserted-by":"publisher","first-page":"7010","DOI":"10.1128\/IAI.68.12.7010-7017.2000","volume":"68","author":"E Cario","year":"2000","unstructured":"Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010\u20137.","journal-title":"Infect Immun"},{"key":"1114_CR55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.5588\/ijtld.12.0600","volume":"17","author":"S Pugazhendhi","year":"2013","unstructured":"Pugazhendhi S, Jayakanthan K, Pulimood AB, Ramakrishna BS. Cytokine gene expression in intestinal tuberculosis and Crohn\u2019s disease. Int J Tuberc Lung Dis. 2013;17:662\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1114_CR56","doi-asserted-by":"publisher","first-page":"20431","DOI":"10.1074\/jbc.M110333200","volume":"277","author":"MT Abreu","year":"2002","unstructured":"Abreu MT, Arnold ET, Thomas LS, et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem. 2002;277:20431\u20137.","journal-title":"J Biol Chem"},{"key":"1114_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1128\/jb.155.1.153-158.1983","volume":"155","author":"W Strittmatter","year":"1983","unstructured":"Strittmatter W, Weckesser J, Salimath PV, et al. Nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides ATCC 17023. J Bacteriol. 1983;155:153\u20138.","journal-title":"J Bacteriol."},{"key":"1114_CR58","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1038\/srep07657","volume":"5","author":"MA Anwar","year":"2015","unstructured":"Anwar MA, Panneerselvam S, Shah M, et al. Insights into the species-specific TLR4 signaling mechanism in response to Rhodobacter sphaeroides lipid A detection. Sci Rep. 2015;5:7657.","journal-title":"Sci Rep."},{"key":"1114_CR59","first-page":"2859135","volume":"2018","author":"M Molteni","year":"2018","unstructured":"Molteni M, Bosi A, Rossetti C. Natural products with toll-like receptor 4 antagonist activity. Int J Inflam. 2018;2018:2859135.","journal-title":"Int J Inflam."},{"key":"1114_CR60","doi-asserted-by":"publisher","first-page":"e0203907-e","DOI":"10.1371\/journal.pone.0203907","volume":"13","author":"A Schink","year":"2018","unstructured":"Schink A, Neumann J, Leifke AL, et al. Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects. PLOS One. 2018;13:e0203907-e.","journal-title":"PLOS One"},{"key":"1114_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1128\/iai.59.1.441-444.1991","volume":"59","author":"N Qureshi","year":"1991","unstructured":"Qureshi N, Takayama K, Kurtz R. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun. 1991;59:441\u20134.","journal-title":"Infect Immun."},{"key":"1114_CR62","doi-asserted-by":"publisher","first-page":"34221","DOI":"10.1038\/srep34221","volume":"6","author":"G Malgorzata-Miller","year":"2016","unstructured":"Malgorzata-Miller G, Heinbockel L, Brandenburg K, et al. Bartonella quintana lipopolysaccharide (LPS): structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applications. Sci Rep. 2016;6:34221.","journal-title":"Sci Rep."},{"key":"1114_CR63","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/13880209.2015.1024330","volume":"54","author":"A Wang","year":"2016","unstructured":"Wang A, Xiao Z, Zhou L, et al. The protective effect of atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture. Pharm Biol. 2016;54:146\u201350.","journal-title":"Pharm Biol."},{"key":"1114_CR64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbi.2016.10.012","volume":"60","author":"C Balducci","year":"2017","unstructured":"Balducci C, Frasca A, Zotti M, et al. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by beta-amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain Behav Immunol. 2017;60:188\u201397.","journal-title":"Brain Behav Immunol."},{"key":"1114_CR65","first-page":"50","volume":"4","author":"K Yuan","year":"2017","unstructured":"Yuan K, Huang G, Zhang S, et al. Celastrol alleviates arthritis by modulating the inflammatory activities of neutrophils. J Tradit Chin Med Sci. 2017;4:50\u20138.","journal-title":"J Tradit Chin Med Sci."},{"key":"1114_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1574-695X.1994.tb00499.x","volume":"9","author":"T Kirikae","year":"1994","unstructured":"Kirikae T, Schade FU, Kirikae F, et al. Diphosphoryl lipid A derived from the lipopolysaccharide (LPS) of Rhodobacter sphaeroides ATCC 17023 is a potent competitive LPS inhibitor in murine macrophage-like J774.1 cells. FEMS Immunol Med Microbiol. 1994;9:237\u201343.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1114_CR67","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2119\/molmed.2012.00020","volume":"18","author":"M De Paola","year":"2012","unstructured":"De Paola M, Mariani A, Bigini P, et al. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971\u201381.","journal-title":"Mol Med."},{"key":"1114_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2016.12.007","volume":"99","author":"V Iori","year":"2017","unstructured":"Iori V, Iyer AM, Ravizza T, et al. Blockade of the IL-1R1\/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiol Dis. 2017;99:12\u201323.","journal-title":"Neurobiol Dis."},{"key":"1114_CR69","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3892\/mmr.2017.6226","volume":"15","author":"P Yao","year":"2017","unstructured":"Yao P, Tan F, Gao H, et al. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid. Mol Med Report. 2017;15:1973\u201380.","journal-title":"Mol Med Report."},{"key":"1114_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1472-6882-14-89","volume":"14","author":"M Chu","year":"2014","unstructured":"Chu M, Ding R, Chu ZY, et al. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4\/MD-2 receptor. BMC Complement Altern Med. 2014;14:89.","journal-title":"BMC Complement Altern Med."},{"key":"1114_CR71","doi-asserted-by":"publisher","first-page":"26470","DOI":"10.1074\/jbc.M111.227934","volume":"286","author":"Q Liang","year":"2011","unstructured":"Liang Q, Wu Q, Jiang J, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286:26470\u20139.","journal-title":"J Biol Chem."},{"key":"1114_CR72","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/abbs\/gmv019","volume":"47","author":"S Li","year":"2015","unstructured":"Li S, Gao X, Wu X, et al. Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells. Acta Biochim Biophys Sin. 2015;47:368\u201375.","journal-title":"Acta Biochim Biophys Sin."},{"key":"1114_CR73","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1165\/rcmb.2006-0323OC","volume":"36","author":"A Saadane","year":"2007","unstructured":"Saadane A, Masters S, DiDonato J, et al. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol. 2007;36:728\u201336.","journal-title":"Am J Respir Cell Mol Biol."},{"key":"1114_CR74","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1189\/jlb.1206727","volume":"82","author":"H Gradi\u0161ar","year":"2007","unstructured":"Gradi\u0161ar H, Keber MM, Pristov\u0161ek P, et al. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol. 2007;82:968\u201374.","journal-title":"J Leukoc Biol."},{"key":"1114_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1742-2094-11-59","volume":"11","author":"H-T Zhu","year":"2014","unstructured":"Zhu H-T, Bian C, Yuan J-C, et al. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4\/MyD88\/NF-\u03baB signaling pathway in experimental traumatic brain injury. J Neuroinflammation. 2014;11:59.","journal-title":"J Neuroinflammation"},{"key":"1114_CR76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejphar.2015.08.022","volume":"765","author":"JL Zhang","year":"2015","unstructured":"Zhang JL, Huang WM, Zeng QY. Atractylenolide I protects mice from lipopolysaccharide-induced acute lung injury. Eur J Pharmacol. 2015;765:94\u20139.","journal-title":"Eur J Pharmacol."},{"key":"1114_CR77","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s10753-016-0398-z","volume":"39","author":"Z Li","year":"2016","unstructured":"Li Z, Xiao X, Yang M. Asiatic acid inhibits lipopolysaccharide-induced acute lung injury in mice. Inflammation. 2016;39:1642\u20138.","journal-title":"Inflammation."},{"key":"1114_CR78","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jep.2015.06.028","volume":"172","author":"JY Lee","year":"2015","unstructured":"Lee JY, Lee BH, Kim ND, et al. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4\/myeloid differentiation factor2 complex in a thiol-dependent manner. J Ethnopharmacol. 2015;172:254\u201360.","journal-title":"J Ethnopharmacol."},{"key":"1114_CR79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.intimp.2007.12.017","volume":"8","author":"YC Cho","year":"2008","unstructured":"Cho YC, Kim HJ, Kim YJ, et al. Differential anti-inflammatory pathway by xanthohumol in IFN-gamma and LPS-activated macrophages. Int Immunopharmacol. 2008;8:567\u201373.","journal-title":"Int Immunopharmacol."},{"key":"1114_CR80","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2011.558190","volume":"7","author":"A Barochia","year":"2011","unstructured":"Barochia A, Solomon S, Cui X, et al. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol. 2011;7:479\u201394.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1114_CR81","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bjp.0702596","volume":"127","author":"T Kawata","year":"1999","unstructured":"Kawata T, Bristol JR, Rossignol DP, et al. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide. Br J Pharmacol. 1999;127:853\u201362.","journal-title":"Br J Pharmacol."},{"key":"1114_CR82","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1128\/AAC.42.11.2824","volume":"42","author":"S Kobayashi","year":"1998","unstructured":"Kobayashi S, Kawata T, Kimura A, et al. Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Antimicrob Agents Chemother. 1998;42:2824\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"1114_CR83","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1124\/jpet.102.044487","volume":"304","author":"M Mullarkey","year":"2003","unstructured":"Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093\u2013102.","journal-title":"J Pharmacol Exp Ther."},{"key":"1114_CR84","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1440-1746.2009.06145.x","volume":"25","author":"T Kitazawa","year":"2010","unstructured":"Kitazawa T, Tsujimoto T, Kawaratani H, et al. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol. 2010;25:1009\u201312.","journal-title":"J Gastroenterol Hepatol."},{"key":"1114_CR85","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.transproceed.2010.03.133","volume":"42","author":"M Liu","year":"2010","unstructured":"Liu M, Gu M, Xu D, et al. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc. 2010;42:1539\u201344.","journal-title":"Transplant Proc."},{"key":"1114_CR86","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejphar.2007.06.027","volume":"571","author":"T Sha","year":"2007","unstructured":"Sha T, Sunamoto M, Kitazaki T, et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol. 2007;571:231\u20139.","journal-title":"Eur J Pharmacol."},{"key":"1114_CR87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1440-1681.2008.05121.x","volume":"36","author":"M Kuno","year":"2009","unstructured":"Kuno M, Nemoto K, Ninomiya N, et al. The novel selective toll-like receptor 4 signal transduction inhibitor tak-242 prevents endotoxaemia in conscious Guinea-pigs. Clin Exp Pharmacol Physiol. 2009;36:589\u201393.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"1114_CR88","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-11-8","volume":"11","author":"I Garate","year":"2014","unstructured":"Garate I, Garcia-Bueno B, Madrigal JL, et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation. 2014;11:8.","journal-title":"J Neuroinflammation."},{"key":"1114_CR89","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/jcbfm.2014.240","volume":"35","author":"F Hua","year":"2015","unstructured":"Hua F, Tang H, Wang J, et al. TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia\/reperfusion injury in mice. J Cereb Blood Flow Metab. 2015;35:536\u201342.","journal-title":"J Cereb Blood Flow Metab."},{"key":"1114_CR90","doi-asserted-by":"publisher","first-page":"40791","DOI":"10.1038\/srep40791","volume":"7","author":"L Perrin-Cocon","year":"2017","unstructured":"Perrin-Cocon L, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017;7:40791.","journal-title":"Sci Rep"},{"key":"1114_CR91","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/1753425918798904","volume":"24","author":"C Palmer","year":"2018","unstructured":"Palmer C, Peri F, Neumann F, et al. The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling. Innate Immun. 2018;24:411\u201321.","journal-title":"Innate Immun."},{"key":"1114_CR92","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-019-02799-7","volume":"76","author":"FA Facchini","year":"2020","unstructured":"Facchini FA, Di Fusco D, Barresi S, et al. Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. Eur J Clin Pharmacol. 2020;76:409\u201318.","journal-title":"Eur J Clin Pharmacol."},{"key":"1114_CR93","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.atherosclerosis.2015.08.010","volume":"242","author":"C Huggins","year":"2015","unstructured":"Huggins C, Pearce S, Peri F, et al. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development. Atherosclerosis. 2015;242:563\u201370.","journal-title":"Atherosclerosis."},{"key":"1114_CR94","doi-asserted-by":"publisher","first-page":"25130","DOI":"10.1038\/srep25130","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wu J, Ying S, et al. Discovery of new MD2 inhibitor from chalcone derivatives with anti-inflammatory effects in LPS-induced acute lung injury. Sci Rep. 2016;6:25130.","journal-title":"Sci Rep."},{"key":"1114_CR95","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/jpet.115.222570","volume":"353","author":"Y Wang","year":"2015","unstructured":"Wang Y, Shan X, Dai Y, et al. Curcumin analog L48H37 prevents lipopolysaccharide-induced TLR4 signaling pathway activation and sepsis via targeting MD2. J Pharmacol Exp Ther. 2015;353:539\u201350.","journal-title":"J Pharmacol Exp Ther."},{"key":"1114_CR96","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/FPC.0b013e3283050aff","volume":"18","author":"CP Hodgkinson","year":"2008","unstructured":"Hodgkinson CP, Ye S. Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenet Genomics. 2008;18:803\u201313.","journal-title":"Pharmacogenet Genomics."},{"key":"1114_CR97","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1258\/vasc.2011.oa0306","volume":"19","author":"A Katsargyris","year":"2011","unstructured":"Katsargyris A, Klonaris C, Tsiodras S, et al. Statin treatment is associated with reduced toll-like receptor 4 immunohistochemical expression on carotid atherosclerotic plaques: a novel effect of statins. Vascular. 2011;19:320\u20136.","journal-title":"Vascular."},{"key":"1114_CR98","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.4049\/jimmunol.174.10.6416","volume":"174","author":"MM Fort","year":"2005","unstructured":"Fort MM, Mozaffarian A, St\u00f6ver AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005;174:6416.","journal-title":"J Immunol."},{"key":"1114_CR99","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/apt.12727","volume":"39","author":"DT Rubin","year":"2014","unstructured":"Rubin DT, Mody R, Davis KL, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014;39:1143\u201355.","journal-title":"Aliment Pharmacol Ther."},{"key":"1114_CR100","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","volume":"31","author":"RD Cohen","year":"2010","unstructured":"Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"key":"1114_CR101","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1365-2249.2007.03571.x","volume":"151","author":"A Kessel","year":"2008","unstructured":"Kessel A, Toubi E, Pavlotzky E, et al. Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat. Clin Exp Immunol. 2008;151:341\u20137.","journal-title":"Clin Exp Immunol."}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-020-01114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-020-01114-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-020-01114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:41:43Z","timestamp":1744152103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-020-01114-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1007\/s12664-020-01114-y","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JSYT, JKC, PAH, CAP, and JMB declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}